Skip to content

Effect Of Azithromycin in Women at Risk of Preterm Labour

Effect Of Azithromycin On Pregnancy Prolongation In Women at Risk of Preterm Labour

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05971654
Enrollment
200
Registered
2023-08-02
Start date
2023-07-30
Completion date
2024-05-30
Last updated
2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Labor

Keywords

preterm delivery, Azithromycin

Brief summary

The aim of this study is to evaluate the benefit of the addition of azithromycin to standard treatments to prolong pregnancy in women having intact membranes and is at risk of or in preterm labour.

Detailed description

Study Design: Comparative controlled study. Study site : The study will be conducted at the department of Obstetrics and Gynecology at Beni-Suef University Hospital. Study period: The study will be conducted from 15th September 2022 till reaching the target number. Study Population The control group will include pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy. The test group will involve pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus prophylactic azithromycin.:500 mg PO once for 5 days every month. Sample size: The sample size was determined using G\*Power Version 3.1.9.2 \[computer software\] (Franz Faul, Kiel, Germany),Power analysis for a chi-square test was conducted in G-POWER to determine a sufficient sample size using an alpha error of probability of 0.05, power of 0.95, a medium effect size (w = 0.3) and 1 degree of freedom. Based on the aforementioned assumptions, the desired sample size is 145. By calculating 25% drop out, so the least total sample size in both groups will be 200 patients (95 patients in each group). Each patient will be subjected to: Thorough history taking and examination. Investigations: Complete blood picture (CBC), bleeding profile , kidney function tests and liver function tests will be done. Ultrasound: 2D Ultrasound assessing : It will be carried out in Gynecology and Obstetrics department in Beni-Suef University Hospital, ultrasonography criteria: Ultrasound biometry of the fetus is now the gold standard for assessing fetal growth. The measurements most commonly used are the biparietal diameter, head circumference, abdominal circumference and femur length

Interventions

DRUGazithromycin

azithromycin.:500 mg PO once for 5 days every month

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* 24 \< Pregnancy \<37 weeks of gestation. * Threat or history of preterm labour. * Preterm labour itself (Non established)

Exclusion criteria

* antibiotics use within 14 days (except for pericerclage prophylaxis, or streptococcus B prophylaxis); * PPROM; and fetal extraction required \<37 weeks. * Current or past history of medical diseases (Diabetes Milletus, Hypertension, Systemic Lupus Erythematosus, Cardiac diseases, etc ). * Adverse perinatal outcome due to abdominal trauma. * Structural fetal anomalies detected during anomaly scan. * Allergy to Azithromycin.

Design outcomes

Primary

MeasureTime frameDescription
Gestational age at time of delivery9 monthsmeasured in week's days'number

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026